Targeted protein degradation (TPD) is transforming drug discovery by leveraging the cell’s natural protein disposal systems ...

Kangpu Biopharmaceuticals, Ltd. announced today that the Center for Drug Evaluation (CDE) of China's National Medical ...

Key scientific achievements expand the pipeline of high value molecular glue degraders for unmet medical needs ...

Evotec SE has announced substantial progress in its strategic research collaboration with Bristol Myers Squibb.

Evotec SE has reached key milestones in its molecular glue degrader collaboration with Bristol Myers Squibb, earning $75 million in performance- ...

Breakthrough research could make any IV drug able to be taken orally for a range of hard-to-treat cancers and other diseases, and redefine how medicines are designed, evaluated and delivered.

Evotec announces progress in strategic protein degradation research collaboration with Bristol Myers Squibb: Hamburg, Northern Germany Saturday, April 26, 2025, 13:00 Hrs [IST] Ev ...

Evotec announced in May of 2022 that the Company has further extended and expanded its collaboration with Bristol Myers Squibb for another 8 years as the initial collaboration proved to be highly ...